title: rhTSH-aided low-activity versus high-activity regimens of radioiodine in residual ablation for differentiated thyroid cancer: a meta-analysis.
abstract: The effects of low-activity versus high-activity radioiodine regimens in thyroid remnant ablation for patients with differentiated thyroid carcinoma (DTC) under recombinant human thyrotropin (rhTSH) stimulation have been widely quoted but there has been no systematic review of the evidence. We undertook a systematic review of randomized controlled trials to assess the effects of low-activity radioiodine in thyroid remnant ablation in patients with DTC under rhTSH stimulation compared with high-activity radioiodine. Studies were obtained from computerized searches of MEDLINE, EMBASE, and the Cochrane Library (all until September 2012). Randomized controlled trials were included. Altogether, 637 patients with DTC who participated in three trials for residual ablation were included. Overall, studies had a low risk of bias. We found no statistically significant differences between low-activity (1.11/1.85 GBq) and high-activity (3.7 GBq) radioiodine treatment aided by rhTSH in terms of successful ablation rates on the basis of diagnostic scans [odds ratio (OR) 0.85, 95% confidence interval (CI) 0.49-1.47, P=0.56], thyroglobulin levels (OR 0.66, 95% CI 0.38-1.15, P=0.14), and health-related quality of life (mean difference 0.07, 95% CI -0.96 to 1.09, P=0.9). In addition, the subgroup analysis of 1.11 versus 3.7 GBq (OR 0.83, 95% CI 0.46-1.49, P=0.53) and 1.85 versus 3.7 GBq (OR 1, 95% CI 0.23-4.35, P=1) also showed no significant differences. The lower activity of 1.11 GBq showed significant benefit in terms of reduction in adverse events including neck pain, radiation gastritis, and salivary dysfunction during and after ablation (OR 0.63, 95% CI 0.42-0.93, P=0.02). Limited data from three randomized controlled trials suggested that an rhTSH-aided low radioiodine activity level of as low as 1.115 GBq may be sufficient for thyroid remnant ablation when compared with 3.7 GBq, with fewer common adverse effects in patients with metastasis-free DTC. Further evidence is needed to confirm the effects of low-activity radioiodine for thyroid remnant ablation. Radioiodine treatment of 1.11 GBq showed significant benefit in terms of reduction in adverse events including neck pain, radiation gastritis, and salivary dysfunction during and after ablation (OR 0.63, 95% CI 0.42-0.93, P=0.02). rhTSH-aided low radioiodine activity levels of 1.11 and 1.85 GBq are sufficient for thyroid remnant ablation as compared with 3.7 GBq, with fewer common adverse effects in patients with metastasis-free DTC. A well-designed study that compares low-activity with high-activity radioiodine ablation is needed to fully understand the long-term adverse effects and relapse or metastases.
authors.affiliation: aDepartment of Nuclear Medicine, Affiliated Xinhua Hospital School of Medicine Shanghai Jiaotong University, Shanghai bDepartment of Radiology, Affiliated Hospital of Medical School, Qingdao University, Qingdao, China.
authors.forename: Chao
authors.initials: C
authors.lastname: Ma
authors.forename: Limin
authors.initials: L
authors.lastname: Tang
authors.forename: Hongliang
authors.initials: H
authors.lastname: Fu
authors.forename: Jianing
authors.initials: J
authors.lastname: Li
authors.forename: Hui
authors.initials: H
authors.lastname: Wang
mesh_terms: D055011:Ablation Techniques / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use; D011788:Quality of Life; D011994:Recombinant Proteins / Q000494:pharmacology*; D013964:Thyroid Neoplasms / Q000473:pathology / Q000628:therapy*; D013972:Thyrotropin / Q000494:pharmacology*
chemical_list: D007457:Iodine Radioisotopes; D011994:Recombinant Proteins; D013972:Thyrotropin
references.citation: N Engl J Med. 2012 May 3;366(18):1663-73
references.pmid: 22551127
references.citation: J Clin Endocrinol Metab. 2013 Jul;98(7):2693-700
references.pmid: 23626005
references.citation: J Nucl Med. 2006 Apr;47(4):648-54
references.pmid: 16595499
references.citation: Cochrane Database Syst Rev. 2010 Nov 10;(11):CD008302
references.pmid: 21069705
references.citation: Nucl Med Commun. 2007 Mar;28(3):215-23
references.pmid: 17264781
references.citation: Cancer. 1996 Jun 15;77(12):2574-80
references.pmid: 8640708
references.citation: Thyroid. 2009 May;19(5):451-7
references.pmid: 19281429
references.citation: Eur J Endocrinol. 2006 Sep;155(3):405-14
references.pmid: 16914594
references.citation: N Engl J Med. 2012 May 3;366(18):1674-85
references.pmid: 22551128
references.citation: Nucl Med Commun. 2006 Aug;27(8):627-32
references.pmid: 16829763
references.citation: Eur J Endocrinol. 2009 Mar;160(3):431-6
references.pmid: 19074463
references.citation: Eur J Endocrinol. 2007 Jan;156(1):13-9
references.pmid: 17218721
references.citation: J Clin Endocrinol Metab. 2002 Sep;87(9):4063-8
references.pmid: 12213846
references.citation: J Nucl Med. 2002 Nov;43(11):1482-8
references.pmid: 12411552
references.citation: Biomed Pharmacother. 2007 Sep;61(8):468-71
references.pmid: 17553654
references.citation: Br J Cancer. 2003 Nov 3;89(9):1638-44
references.pmid: 14583762
references.citation: Ann Nucl Med. 2006 Jan;20(1):63-7
references.pmid: 16485577
references.citation: J Clin Endocrinol Metab. 2006 Mar;91(3):926-32
references.pmid: 16384850
references.citation: Intern Med J. 2009 Mar;39(3):156-63
references.pmid: 19383064
references.citation: J Clin Endocrinol Metab. 2006 May;91(5):1819-25
references.pmid: 16478820
references.citation: Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1457-63
references.pmid: 18385999
references.citation: J Nucl Med. 2008 May;49(5):764-70
references.pmid: 18413378
references.citation: Thyroid. 2005 Oct;15(10):1147-55
references.pmid: 16279848
references.citation: J Clin Endocrinol Metab. 2007 Sep;92(9):3542-6
references.pmid: 17609306
references.citation: J Nucl Med. 2008 Nov;49(11):1776-82
references.pmid: 18927337